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S U M M A R Y
Mathematical modelling is increasingly used to inform
budgeting and strategic decision-making by national
TB programmes. Despite the importance of these
decisions, there is currently no mechanism to review
and confirm the appropriateness of modelling analyses.
We have developed a benchmarking, reporting, and
review (BRR) approach and accompanying tools to
allow constructive review of country-level TB model-
ling applications. This approach has been piloted in five
modelling applications and the results of this study
have been used to revise and finalise the approach. The
BRR approach consists of 1) quantitative benchmarks
against which model assumptions and results can be
compared, 2) standardised reporting templates and
review criteria, and 3) a multi-stage review process
providing feedback to modellers during the application,
as well as a summary evaluation after completion.
During the pilot, use of the tools prompted important
changes in the approaches taken to modelling. The
pilot also identified issues beyond the scope of a review
mechanism, such as a lack of empirical evidence and
capacity constraints. This approach provides indepen-
dent evaluation of the appropriateness of modelling
decisions during the course of an application, allowing
meaningful changes to be made before results are used
to inform decision-making. The use of these tools can
improve the quality and transparency of country-level
TB modelling applications.
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The use of mathematical modelling to support TB
policy-making has been encouraged by major funding
agencies and adopted by many high-burden coun-
tries. These quantitative planning exercises are
undertaken to prioritise proposed interventions,
estimate resource needs and support funding appli-
cations. Over the past 2 years alone, the number of
countries using TB modelling to develop national
strategic plans or inform funding applications has
doubled from around 20 to 40.1 The increased use of
modelling has also highlighted differences in the
findings of individual modelling studies. Model
comparison exercises for TB2–4 and other diseases5–8
have revealed that differences in results occur even
when models evaluate the same policy alternatives in
the same setting. In some cases, these differences are
of sufficient magnitude to influence the policy
conclusions drawn. This variability threatens to
undermine confidence in modelling for decision-
making. There is also concern that modelling for
new policy options may be overly optimistic if it does
not anticipate the implementation challenges encoun-
tered during roll-out.9 Major uncertainties in the
empirical evidence base10 mean that different models
should not always be expected to align, but there is
currently no mechanism to ensure the quality of
modelling applications, and it is possible that choices
about model structure and inputs could be improved
through independent review.
Academic journals have a long tradition of
independent peer-review to assess the quality of
published work. However, these peer review mecha-
nisms are not designed to test the modelling for
country-level decision-making. Instead, modelling is
typically subjected to peer-review after country-level
decision-making is complete, if at all. Given the
iterative nature and hard deadlines of country
planning processes, traditional journal review is
therefore unlikely to provide appropriate and timely
input, as decisions will already have been made by the
time feedback has been received. In addition, such
review tends to focus on the technical quality of the
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work and how it is communicated as an academic
manuscript,11 and less attention is given to the
process of stakeholder engagement and how model-
ling results and limitations are communicated to this
key group.
In 2018, the WHO and the TB Modelling and
Analysis Consortium (TB MAC) published guidance
for mathematical modelling used to support country-
level TB decision-making, consolidating inputs from
a wide range of stakeholders.12,13 The guidance
describes principles and good practices for country-
level modelling, but does not describe how these
principles should be operationalized. This encour-
aged individual modelling groups to ensure that good
practices were followed, but without a clear mecha-
nism to confirm that this had occurred. To respond to
this need, we have developed an approach designed to
evaluate the quality of individual modelling applica-
tions and strengthen the incentives for quality and
transparency of these studies. Here we describe the
development and piloting process, and the finalised
approach.
DESIGN CONSIDERATIONS
We developed the benchmarking, reporting and
review (BRR) approach to reveal where a given
modelling application is inconsistent with existing
evidence or modelling best-practices,13 and provide
feedback to modellers that can be used to revise the
analysis. Supplementary Table S1 describes proximal,
intermediate and final objectives of the approach.
Several considerations for the design of the approach
were highlighted during conceptualisation. First, due
to the importance of contextual factors in determin-
ing the appropriateness of modelling methods, the
approach should evaluate the adequacy of modelling
as used in a specific application, rather than
attempting a global assessment of model validity.
Second, the review should consider not only the
technical quality of modelling, but also the level of
engagement with stakeholders within the modelling
application, responsiveness to country needs and
clarity of dissemination, as these are equally impor-
tant in determining the value of modelling for
decision-making. Third, the review should provide
feedback to modellers during the course of the
application, which can be incorporated before
analyses are finalised. Fourth, given the range of
reasonable modelling approaches that could be
adopted, the results of the review should not be
prescriptive, and modellers should be able to provide
a response justifying their chosen approach. Fifth,
modelling applications require a range of expertise,
including TB programme strategy, epidemiological
modelling and economics, and the reviewer(s) should
be able to cover these domains.
DEVELOPMENT PROCESS
An initial approach was prepared by a small writing
committee, and further developed by a working
group of modellers, economists, TB programme
experts and donor representatives. This approach
was presented at the 2018 WHO/TB MAC annual
meeting in Washington DC, USA,14 where input was
invited from a wider stakeholder group that included
modelling groups, economists, country stakeholders,
funders, advocates and other technical experts. The
approach was piloted in a sample of five country-level
modelling applications, and additional input was
obtained at the 2019 WHO/TB MAC annual meeting
in Istanbul, Turkey.15
PILOT STUDY
We piloted the BRR approach in five country-level
modelling applications conducted between 2018 and
2020 for high TB burden countries using modelling
technical assistance to develop funding requests for
one of several funding agencies. These included a
variety of settings (Kenya, Bhutan, Indonesia,
Mongolia, Myanmar); several funding agencies
(The Bill and Melinda Gates Foundation, the Global
Fund, the United States Agency for International
Development); and different modelling groups (Im-
perial College London, the Australian Tuberculosis
Modelling Network and the London School of
Hygiene & Tropical Medicine). Policy questions
addressed included the prioritisation and cost-
effectiveness of interventions for strategic planning,
resource allocation, the development of targets and
programmatic strategy required to reach targets. For
each review, we engaged three independent review-
ers, with expertise in epidemiological modelling,
economics and TB programme strategy, respectively.
After each completed review, we conducted inter-
views with modellers and reviewers to assess their
experience with the review process (see Supplemen-
tary Data). This feedback was used to revise and
finalise the approach.
Ethical approval was not required for the study as
it did not involve human participants.
PILOT STUDY EVALUATION
Modellers participating in the pilot study reported
that the BRR approach provided a structure that
added clarity and standardisation to the review, and
that the review feedback led modellers to reconsider
modelling approaches and how these were commu-
nicated. Examples of these changes included remov-
ing intervention scenarios for which empirical
evidence was weak, and more explicit description of
uncertainties and costs. Participants considered the
BRR to have improved the transparency and quality
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of modelling applications, and also suggested mod-
ified modelling approaches they would apply to
future applications. Participants reported the tem-
plates and benchmarks were detailed and useful, and
the process provided sufficient flexibility and oppor-
tunity to raise disagreements. However, several
participants reported that the time required to
participate in the review could conflict with the
timing of the modelling application. Participants
noted that competing priorities and tight deadlines
of the country planning process meant that reviews
frequently needed to be completed urgently, and
modellers had limited time to incorporate feedback.
In one application, stakeholders required the model-
ling to be finalised before the final stages of review
could be completed. Detailed feedback is included in
Supplementary Data. The approach was revised
based on the results of this pilot, including revisions
to the text of individual forms and streamlining of the
review process to better accommodate tight dead-
lines. The final approach is described below.
THE BENCHMARKING, REPORTING, AND
REVIEW APPROACH
The BRR approach comprises 1) quantitative bench-
marks describing features of TB natural history,
epidemiology, health services, and costs; 2) a standard
format for reporting modelling methods for review,
and additional templates to standardise the review
process; and 3) a standard process for external review.
Materials for implementing this approach are pro-
vided in Supplementary Data with an overview of the
approach shown in the Figure.
Benchmarks
The benchmarks describe features of TB epidemiol-
ogy and economics about which assumptions need to
be made as part of the modelling application, and
where independent evidence is available to judge the
appropriateness of assumptions. Table 1 lists the
major domains covered by these benchmarks. The
benchmarks are divided into epidemiological and
economic benchmarks, including general bench-
marks, assumed to apply to all settings (for example,
assumptions around TB natural history in immuno-
competent adults); and country-specific benchmarks,
where the benchmark value will vary between settings
and over time (for example, modelled TB burden
estimates could be compared to published values for
the same country and year). Modelling assumptions
can be compared to these benchmarks to assess their
appropriateness for a given policy question and
country context. The benchmarks also include a
standard set of modelling results and projections for
which no formal comparison value may exist (such as
future epidemiological trends in the base-case mod-
elling scenario), but which aid interpretation of the
model results. The full set of benchmarks is provided
in the Supplementary Data.
Although the benchmarks are intended to apply to
most modelling scenarios, it is possible that specific
modelling assumptions or results may deviate from
these benchmarks due to unique features of the
setting or population of interest. In this situation,
modellers are not expected to modify their model to
meet the benchmark, but instead to note the
discrepancy and provide a satisfactory justification
to explain the difference.
Figure Flowchart of a typical review process, identifying actors and contact points in the review
process. Different shading and columns indicate different actors in the review process. Arrows
indicate the actor responsible for a particular step (arrow origin column) and the recipient (arrow
destination column).
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Reporting format
Standard reporting templates are used to summarise
key features of the modelling application for the
purpose of review. Table 2 lists major domains
covered by these templates, which include quantita-
tive outcomes (including the benchmarks described
above), a description of the modelling context and
evaluation questions addressed, and key features of
the modelling process. Modellers can also provide
additional documentation (such as published papers
or technical reports). Standardised templates are also
provided for reviewers to record their review report.
The templates are designed to be sufficiently general
in nature to apply to all modelling applications, with
clear instructions for what to do for optional sections.
These templates are provided in the Supplementary
Data.
External review
The Figure provides a flow diagram of a typical
Table 1 Domains covered by modelling benchmarks*
Benchmark area Description
General epidemiological benchmarks Describe general features of TB epidemiology, and are assumed to apply to most settings in
which TB is being modelled to evaluate policy/intervention options. Unless otherwise stated,
benchmarks apply to the HIV-negative general population. Disease definitions (active TB,
latent TB) follow standard definitions described by the WHO, as operationalised in the model.
For models that provide a range of results (stochastic models or probabilistic analyses)




Describe country-specific features of TB epidemiology. Modellers can make comparisons with
the series of estimates most appropriate to their estimation task; possible options are shown




Describe features of TB programme resource utilisation that are assumed to be country-specific.
Modellers can make comparisons with the data/estimates most appropriate to their estimation
task
Additional standard outputs Describe features of TB epidemiology and programme performance for which no benchmark is
provided, but which are useful for interpreting model assumptions and results
Policy projections Describe modelled epidemiological outcomes
* Full tables of benchmarks are provided in the reporting templates.
Table 2 Summary of the final reporting domains*
Reporting domain Reporting areas
Evaluation question  What is the primary research question for modelling? What is the primary audience for modelling results?
 What is the population being modelled, and are there sub-populations of particular interest?
 What policy alternatives are compared, and how were these identified?
 What outcomes are used to summarise health or epidemiological effects of policy alternatives?
 What type of economic analysis is being conducted, and what are the primary metrics used to report economic
results?
 How are optimal policies chosen?
Process  Which stakeholders (local partners, funders, technical agencies or others) are participating in the modelling
application?
 What activities are being undertaken to support local capacity building or institutionalisation?
 Are there any conflicts of interest (including the review process, if relevant)?
Results  What are the main findings and policy recommendations of the modelling?
 What are the major uncertainties or untested assumptions of this modelling? How were these limitations
presented to decision-makers?
 What are the major threats to success of the novel policies examined?
 What is the most urgent or important research needed to confirm these findings?
 How will these modelling results be used in the policy process?
Benchmarks  Are results consistent with modelling benchmarks and other relevant comparison data?
 If there are deviations, how should these be interpreted?
 Are other steps being taken to validate the model?
 What uncertainty and sensitivity analyses are conducted, and what conclusions are drawn from these for policy
recommendations?
 Describe the technical specifications of the economic analysis.
 Is empirical evidence available to support assumptions around the magnitude of changes in intervention
coverage, quality or effectiveness, by intervention?
 Is there a more detailed model report that provides technical details of the model approach, including model
structure, parameterisation, cost estimates or functions, application setting and results?
* Reporting and review templates for each stage of review are provided in the Supplementary Data.
A review mechanism for TB modelling 617
review process, including the actors involved and
steps taken to complete the review. The review itself is
divided into two stages, and it is important to develop
a shared timeline for the process as soon as possible to
ensure that the review fits the requirements of the
modelling application. The first-stage review evaluates
initial results and is timed so that feedback can be used
to adjust modelling decisions, if deemed appropriate
by the modellers. The second-stage review considers
finalised modelling results and provides a summary
appraisal of the strengths and weakness of the
modelling application. Supplementary Table S2 lists
the high-level criteria against which independent
external reviewers (not affiliated with the modelling
team, funder or stakeholders) evaluate the modelling
application, based on principles for good modelling
practice described in the WHO Guidance for Country-
Level TB Modelling.13 For each stage of review, the
modelling team is expected to complete the reporting
template, which is then sent to the reviewers to
complete the review template and return the review.
A discussion between the modelling team and review-
ers may then be held to allow questions and
clarifications. In the second-stage review, any unre-
solved areas of disagreement are noted and included in
the final review report, including the recommended
change and the response from the modelling team. The
reviewers and the modelling group are asked to sign
off on the completed final review and response, which
is included in the final report. This report is shared
with a list of recipients agreed at the start of the review.
In situations where external review is not possible,
modellers can undertake self-review using the BRR
materials and compare modelling results to the
benchmarks.
DISCUSSION
The BRR approach represents a first attempt, outside
of peer review of an academic article, to establish a
routine peer-review process for mathematical model-
ling as part of country-level disease control strategy
development. This approach establishes a platform
for discussions between modellers and reviewers,
enabling a constructive review of the modelling
application. It can identify and resolve any areas
where the application is inconsistent with existing
evidence or best-practice modelling approaches,
strengthening the evidence used to support decision-
making. This approach does not attempt to draw
broad conclusions about the validity of the models
being used, but rather focuses on the appropriateness
of modelling for a specific setting and policy question.
For this reason, the approach is intended to comple-
ment periodic multi-model comparison studies16 (as
have been conducted for TB,2–4 HIV,5,8 malaria,7
vaccine-preventable diseases,6,17 and COVID-1918),
which allow direct comparisons between models but
cannot address all the context-specific factors rele-
vant to a given modelling application. While the
approach is designed for routine use there may be
some modelling applications where external review is
not needed, such as small updates to earlier models.
The decision to undertake external review will
ultimately be made by the stakeholders in a given
modelling application.
In a pilot study of the BRR approach conducted
alongside five country-level modelling applications,
participants reported that the reviewer feedback
prompted improvements in the approaches taken to
modelling by identifying intervention scenarios with
insufficient empirical support. Modellers also report-
ed that the process provided feedback to improve
modelling methods and increased stakeholder confi-
dence in the findings, without being overly prescrip-
tive. However, issues with the coordination and
timing of the review were reported. The stop-start
nature of the country-level planning processes,
combined with tight deadlines, meant that it was
difficult at times to provide meaningful review in a
way that could be incorporated into the modelling.
Because of this experience, the approach was revised
and streamlined. This pilot study provides initial
evidence on how independent review can play a
constructive role in country-level modelling applica-
tions, but additional steps to evaluate the impact of
the BRR approach will be needed as it is used more
routinely. It is expected that the BRR approach will
require periodic revision as the role of modelling to
support country strategic planning evolves over time.
In particular, as national strategic plans are more
directly linked to Global Fund funding requests, this
will have a knock-on effect on the requirements of
modelling, particularly around timing.
The development and piloting process revealed
several challenges for country-level TB modelling
beyond the scope of the BRR approach. First, a lack
of high-quality empirical evidence was mentioned by
a number of pilot study participants, limiting the
ability of models to accurately represent complex
scenarios or novel interventions. Second, as the
approach only assesses a single modelling application
at a time, it does not directly assess the variation in
results possible with different models, yet this is still a
concern in the field. Third, human capacity con-
straints and staff turnover, for both modelling groups
and in-country stakeholders, can be a challenge to
continuity and process improvement. These issues
echo problems identified in the development of earlier
guidance,12 and will likely require solutions beyond
the BRR approach.
Increasing the alignment of modelling applications
with standardised planning processes – most notably
those following the WHO-endorsed People-Centred
Framework for TB Programme Planning and Priori-
tization19 – will help ensure that modelling evidence
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is integrated into planning cycles, that routinely
collected data can inform modelling applications
and that models are better prepared to answer new
policy questions. Institutionalisation of the review
process within a funding body or major technical
agency would be beneficial, providing a unit to
identify modelling applications for review and
coordinate these reviews. This institutionalisation
would provide continuity for the review mechanism
and better align the incentives modellers face. In
parallel to these efforts to institutionalise external
reviews for modelling applications, new research is
needed to strengthen the empirical evidence base for
modelling and investigate other sources of variation
in modelling results.
CONCLUSION
The BRR approach is designed to improve the quality
and usefulness of TB modelling used for country-level
decision-making. If routinely implemented, this
approach will strengthen the incentives for high-
quality modelling work, identify common areas
where modelling methods or the empirical evidence
base need to be strengthened, and stimulate the
progressive improvement of TB modelling as a tool to
inform country-level TB strategy.
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R É S U M É
Les programmes nationaux de lutte contre la TB ont de
plus en plus recours aux modélisations mathématiques
pour éclairer l’établissement du budget et la prise de
décision stratégique. Malgré l’importance de ces
décisions, il n’existe actuellement aucun mécanisme
permettant de vérifier et confirmer la pertinence des
analyses de modélisation. Nous avons développé une
méthode de référenciation, rapportage et examen (de
l’anglais, benchmarking, reporting and review [BRR]),
avec outils connexes, pour une analyse constructive des
modélisations liées à la TB à l’échelle d’un pays. Cette
approche a été testée avec cinq applications de
modélisation et les résultats de cette étude ont été
utilisés afin de corriger et de finaliser l’approche.
L’approche BRR comprend : 1) des points de référence
quantitatifs avec lesquels les hypothèses et résultats des
modélisations peuvent être comparés, 2) des modèles de
rapports standardisés et des critères d’examen, et 3) un
processus d’examen en plusieurs étapes faisant remonter
les informations aux modélisateurs pendant
l’application du modèle, ainsi qu’une évaluation
récapitulative une fois la modélisation terminée.
Pendant l’essai pilote, l’utilisation d’outils a donné lieu
à d’importantes modifications des approches de
modélisation. L’essai pilote a également permis
d’identifier des problèmes qui sortent du champ
d’application d’un mécanisme d’évaluation, tels qu’un
manque de données probantes empiriques et des
contraintes de capacité. Cette approche fournit une
évaluation indépendante de la pertinence des décisions
de modélisation pendant l’application du modèle,
permettant d’apporter des modifications significatives
avant d’utiliser les résultats pour éclairer la prise de
décisions. L’utilisation de ces outils peut améliorer la
qualité et la transparence des modélisations liées à la TB
à l’échelle d’un pays.
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